Paediatric Drugs

, Volume 3, Issue 9, pp 629–637 | Cite as

Management of the Extremely Preterm Infant

Is the Replacement of Estradiol and Progesterone Beneficial?
Current Opinion

Abstract

This review presents data to suggest that postnatal estradiol and progesterone replacement therapy may be beneficial in preterm infants. During pregnancy, maternal plasma levels of estradiol and progesterone increase up to 100-fold compared to the nonpregnant status. The fetus is also exposed to these increasing hormone levels. After delivery, estradiol and progesterone levels drop by a factor of 100 within 1 day. Whereas this is a physiological condition for an infant born at term, preterm delivery means withdrawal from the placental supply of these hormones at an earlier developmental stage. Seventy years ago, the idea was raised that preterm infants may benefit from the replacement of estrogens. Studies in which estrogen was injected subcutaneously showed only a slightly better bodyweight gain compared to placebo-treated controls and therefore routine use was not established. The effective treatment of postmenopausal osteoporosis with hormone replacement therapy led to a pilot study of estradiol and progesterone therapy to prevent osteopenia of prematurity. The highest median bone mineral accretion rate was found in the replacement group when the supplementation with calcium and phosphorus was also sufficient. None of the previous studies dealing with estrogen replacement controlled for achieved plasma levels of estradiol in the infants. In our controlled randomised pilot study with 30 preterm infants (15 in each group), we aimed to maintain intra-uterine plasma levels of estradiol and progesterone. Preterm infants with replacement of estradiol and progesterone for 6 weeks postnatally showed trends to higher bone mineral accumulation. In addition, a trend towards a lower incidence of chronic lung disease was found. Neurodevelopmental follow-up showed normal psychomotor development in infants given estradiol and progesterone, whereas the untreated infants (controls) showed a trend towards delayed development. Recent research emphasises that estradiol and progesterone may be important for brain development. Thus, while there is data indicating that postnatal estradiol and progesterone replacement therapy may be beneficial in preterm infants, experience with this new therapy is limited and extensive research is needed to address the potential benefits and to rule out adverse effects.

Keywords

Progesterone Estradiol Preterm Infant Stratum Corneum Uterine Volume 

References

  1. 1.
    Aschheim S. Weitere Untersuchungen über Hormone und Schwangerschaft. Arch F Gynak 1927; 132: 179–83CrossRefGoogle Scholar
  2. 2.
    Moncrieff A. The value of oestrin for premature babies. Arch Dis Child 1936; 11: 9–20PubMedCrossRefGoogle Scholar
  3. 3.
    Smith OW. Diethylstilbestrol in the prevention and treatment of complications of pregnancy. Am J Obstet Gynecol 1948; 56: 821–34PubMedGoogle Scholar
  4. 4.
    Dalton K. Ante-natal progesterone and intelligence. Br J Psychiatry 1968; 114: 1377–82PubMedCrossRefGoogle Scholar
  5. 5.
    Dalton K. Prenatal progesterone and educational attainments. Br J Psychiatry 1976; 129: 438–42PubMedCrossRefGoogle Scholar
  6. 6.
    Reinisch JM. Prenatal exposure of human foetuses to synthetic progestin and oestrogen affects personality. Nature 1977; 266: 561–2PubMedCrossRefGoogle Scholar
  7. 7.
    Herbst A, Ulfelder H, Poskanzer D. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971; 284: 878–81PubMedCrossRefGoogle Scholar
  8. 8.
    Sandberg EC, Riffle NL, Higdon JV, et al. Pregnancy outcome in women exposed to diethylstilbestrol in utero. Am J Obstet Gynecol 1981; 140: 194–205PubMedGoogle Scholar
  9. 9.
    Shanklin D, Wolfson S. Aqueous estrogens in the management of respiratory distress syndrome. J Reprod Med 1970; 5: 53–71PubMedGoogle Scholar
  10. 10.
    Plath C, Plesse R, Pelz L. Preliminary results of the preventive treatment of premature infants with estrogens for the prevention of idiopathic respiratory distress syndrome [in German]. Dtsch Gesundheitsw 1976; 31: 2460–2PubMedGoogle Scholar
  11. 11.
    Block MF, Kling OR, Crosby WM. Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstet Gynecol 1977; 50: 186–90PubMedGoogle Scholar
  12. 12.
    Cummings JJ, D’Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for broncho-pulmonary dysplasia. N Engl J Med 1989; 320: 1505–10PubMedCrossRefGoogle Scholar
  13. 13.
    Siler-Khodr TM. Endocrine and paracrine function of the human placenta. In: Polin RA, Fox WW, editors. Fetal and neonatal physiology. Philadelphia (PA): WB Saunders, 1992: 74–85Google Scholar
  14. 14.
    Tulchinsky D, Hobel CJ, Yeager E, et al. Plasma estrone, estra-diol, estriol, progesterone, and 17-hydroxyprogesterone in human pregnancy (I): normal pregnancy. Am J Obstet Gynecol 1972; 112: 1095–100PubMedGoogle Scholar
  15. 15.
    Hercz P. Quantitative changes in steroid and peptide hormones in the maternal-fetoplacental system between the 28th–40th weeks of pregnancy. Acta Med Hung 1985; 42: 29–39PubMedGoogle Scholar
  16. 16.
    Dvoracsek E, Kassai Z, Torok I, et al. Sexual steroid levels and their clinical significance in the early neonatal age. Acta Physiol Hung 1990; 76: 151–8PubMedGoogle Scholar
  17. 17.
    Conly PW, Morrison T, Sandberg DH, et al. Concentrations of progesterone in the plasma of mothers and infants at time of birth. Pediatr Res 1970; 4: 76–81PubMedCrossRefGoogle Scholar
  18. 18.
    Kenny FM, Angsusingha K, Stinson D, et al. Unconjugated estrogens in the perinatal period. Pediatr Res 1973; 7: 826–31PubMedCrossRefGoogle Scholar
  19. 19.
    Hercz P, Ungar L, Siklos P, et al. Unconjugated 17 beta-oestradiol and oestriol in maternal serum and in cord vein and artery blood at term and preterm delivery. Eur J Obstet Gynecol Reprod Biol 1988; 27: 7–12PubMedCrossRefGoogle Scholar
  20. 20.
    Tayama C, Ichimaru S, Ito M, et al. Unconjugated estradiol, estriol and total estriol in maternal peripheral vein, cord vein, and cord artery serum at delivery in pregnancies with intra-uterine growth retardation. Endocrinol Jpn 1983; 30: 155–62PubMedCrossRefGoogle Scholar
  21. 21.
    Herruzo AJ, Mozas J, Alarcon JL, et al. Sex differences in serum hormone levels in umbilical vein blood. Int J Gynaecol Obstet 1993; 41: 37–41PubMedCrossRefGoogle Scholar
  22. 22.
    Scommegna A, Burd L, Bieniarz J. Progesterone and pregneno-lone sulfate in pregnancy plasma. Am J Obstet Gynecol 1972; 113: 60–5PubMedGoogle Scholar
  23. 23.
    Sippell WG, Becker H, Versmold HT, et al. Longitudinal studies of plasma aldosterone, corticosterone, deoxycorticosterone, progesterone, 17-hydroxyprogesterone, cortisol, and cortisone determined simultaneously in mother and child at birth and during the early neonatal period (I): spontaneous delivery. J Clin Endocrinol Metab 1978; 46: 971–85PubMedCrossRefGoogle Scholar
  24. 24.
    Trotter A, Maier L, Grill HJ, et al. 17β-estradiol and progesterone supplementation in extremely low-birth-weight infants. Pediatr Res 1999; 45: 489–93PubMedCrossRefGoogle Scholar
  25. 25.
    Geola F, Frumar A, Tataryn I, et al. Biological effects of various doses of conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1980; 51: 620–5PubMedCrossRefGoogle Scholar
  26. 26.
    Judd H. Efficacy of transdermal estradiol. Am J Obstet Gynecol 1987; 156: 1326–31PubMedGoogle Scholar
  27. 27.
    Harpin VA, Rutter N. Barrier properties of the newborn infant’s skin. J Pediatr 1983; 102: 419–25PubMedCrossRefGoogle Scholar
  28. 28.
    Ghadially R, Shear NH. Topical therapy and percutaneous absorption. In: Yaffe SJ, Aranda JV, editors. Pediatric pharmacology: therapeutical principles in practice. Philadelphia (PA): WB Saunders, 1992: 72–7Google Scholar
  29. 29.
    Khosla S, Rooney S. Stimulation of fetal lung surfactant production by administration of 17beta-estradiol to the maternal rabbit. Am J Obstet Gynecol 1979; 133: 213–6PubMedGoogle Scholar
  30. 30.
    Chu AJ, Rooney SA. Estrogen stimulation of surfactant synthesis. Pediatr Pulmonol 1985; 1 (3 Suppl.): S110–4PubMedGoogle Scholar
  31. 31.
    Khosla S, Smith G, Parks P, et al. Effects of estrogen on fetal rabbit lung maturation: morphological and biochemical studies. Pediatr Res 1981; 15: 1274–81PubMedCrossRefGoogle Scholar
  32. 32.
    Thuresson-Klein A, Moawad A, Hedqvist P. Estrogen stimulates formation of lamellar bodies and release of surfactant in the rat fetal lung. Am J Obstet Gynecol 1985; 151: 506–14PubMedGoogle Scholar
  33. 33.
    Massaro GD, Mortola JP, Massaro D. Estrogen modulates the dimensions of the lung’s gas-exchange surface area and alveoli in female rats. Am J Physiol 1996; 270 (1 Pt 1): L110–4PubMedGoogle Scholar
  34. 34.
    Connelly I, Hammond G, Harding P, et al. Levels of surfactant-associated protein messenger ribonucleic acids in rabbit lung during perinatal development and after hormonal treatment. Endocrinology 1991; 129: 2583–91PubMedCrossRefGoogle Scholar
  35. 35.
    Beyer C. Estrogen and the developing mammalian brain. Anat Embryol (Berl) 1999; 199: 379–90CrossRefGoogle Scholar
  36. 36.
    Toran-Allerand CD, Hashimoto K, Greenough WT, et al. Sex steroids and the development of the newborn mouse hypothalamus and preoptic area in vitro (III): effects of estrogen on dendritic differentiation. Brain Res 1983; 283: 97–101PubMedGoogle Scholar
  37. 37.
    Toran-Allerand CD. Sex steroids and the development of the newborn mouse hypothalamus and preoptic area in vitro (II): morphological correlates and hormonal specificity. Brain Res 1980; 189: 413–27PubMedCrossRefGoogle Scholar
  38. 38.
    Garcia-Segura LM, Dueñas M, Fernandez-Galaz MC, et al. Interaction of the signalling pathways of insulin-like growth fac-tor-I and sex steroids in the neuroendocrine hypothalamus. Horm Res 1996; 46: 160–4PubMedCrossRefGoogle Scholar
  39. 39.
    Reisert I, Han V, Lieth E, et al. Sex steroids promote neurite growth in mesencephalic tyrosine hydroxylase immunoreac-tive neurons in vitro. Int J Dev Neurosci 1987; 5: 91–8PubMedCrossRefGoogle Scholar
  40. 40.
    Garcia-Segura LM, Olmos G, Robbins RJ, et al. Estradiol induces rapid remodelling of plasma membranes in developing rat cerebrocortical neurons in culture. Brain Res 1989; 498: 339–43PubMedCrossRefGoogle Scholar
  41. 41.
    Hays TC, Goldstein LA, Mills AC, et al. Motoneuron development after deafferentation (II): dorsal rhizotomy does not block estrogen-supported growth in the dorsolateral nucleus (DLN). Brain Res Dev Brain Res 1996; 91: 20–8PubMedCrossRefGoogle Scholar
  42. 42.
    Goldstein LA, Sengelaub DR. Differential effects of dihydro-testosterone and estrogen on the development of motoneuron morphology in a sexually dimorphic rat spinal nucleus. J Neu-robiol 1994; 25: 878–92Google Scholar
  43. 43.
    Matsumoto A. Synaptogenic action of sex steroids in developing an adult neuroendocrine brain. Psychoneuroendocrino-logy 1991; 16:25–40CrossRefGoogle Scholar
  44. 44.
    Ross JL, Kushner H, Roeltgen DP. Developmental changes in motor function in girls with Turner syndrome. Pediatr Neurol 1996; 15: 317–22PubMedCrossRefGoogle Scholar
  45. 45.
    Salbenblatt JA, Meyers DC, Bender BG, et al. Gross and fine motor development in 45,X and 47,XXX girls. Pediatrics 1989; 84: 678–82PubMedGoogle Scholar
  46. 46.
    Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet 1996; 348: 429–32PubMedCrossRefGoogle Scholar
  47. 47.
    Asthana S, Craft S, Baker LD, et al. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer’s disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology 1999; 24: 657–77PubMedCrossRefGoogle Scholar
  48. 48.
    Jung-Testas I, Do Thi A, Koenig H, et al. Progesterone as a neuro-steroid: synthesis and actions in rat glial cells. J Steroid Biochem Mol Biol 1999; 69: 97–107PubMedCrossRefGoogle Scholar
  49. 49.
    Jiang N, Chopp M, Stein D, et al. Progesterone is neuroprotec-tive after transient middle cerebral artery occlusion in male rats. Brain Res 1996; 735: 101–7PubMedCrossRefGoogle Scholar
  50. 50.
    Gonzalez-Vidal MD, Cervera-Gaviria M, Ruelas R, et al. Progesterone: protective effects on the cat hippocampal neuronal damage due to acute global cerebral ischemia. Arch Med Res 1998; 29: 117–24PubMedGoogle Scholar
  51. 51.
    Asbury ET, Fritts ME, Horton JE, et al. Progesterone facilitates the acquisition of avoidance learning and protects against sub-cortical neuronal death following prefrontal cortex ablation in the rat. Behav Brain Res 1998; 97: 99–106PubMedCrossRefGoogle Scholar
  52. 52.
    Thomas AJ, Nockels RP, Pan HQ, et al. Progesterone is neu-roprotective after acute experimental spinal cord trauma in rats. Spine 1999; 24: 2134–8PubMedCrossRefGoogle Scholar
  53. 53.
    Baulieu EE, Schumacher M, Koenig H, et al. Progesterone as a neurosteroid: actions within the nervous system. Cell Mol Neurobiol 1996; 16: 143–54PubMedCrossRefGoogle Scholar
  54. 54.
    Baulieu EE, Schumacher M. Neurosteroids, with special reference to the effect of progesterone on myelination in peripheral nerves. Mult Scler 1997; 3: 105–12PubMedCrossRefGoogle Scholar
  55. 55.
    Lindsay R. Sex steroids in the pathogenesis and prevention of osteoporosis. In: Melton LJ, Riggs L, editors. Osteoporosis: etiology, diagnosis and management. New York (NY): Raven Press, 1988: 333–58Google Scholar
  56. 56.
    Christiansen C, Riis BJ. 17 Beta-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990; 71: 836–41PubMedCrossRefGoogle Scholar
  57. 57.
    Hasling C, Charles P, Jensen FT, et al. A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis. Osteoporos Int 1994; 4: 191–203PubMedCrossRefGoogle Scholar
  58. 58.
    Civitelli R, Agnusdei D, Nardi P, et al. Effects of one-year treatment with estrogens on bone mass, intestinal calcium absorption, and 25-hydroxy vitamin D-1 alpha- hydroxylase reserve in postmenopausal osteoporosis. Calcif Tissue Int 1988; 42: 77–86PubMedCrossRefGoogle Scholar
  59. 59.
    Griscom NT, Craig JN, Neuhauser EB. Systemic bone disease developing in small premature infants. Pediatrics 1971; 48: 883–95PubMedGoogle Scholar
  60. 60.
    James JR, Congdon PJ, Truscott J, et al. Osteopenia of prematurity. Arch Dis Child 1986; 61: 871–6PubMedCrossRefGoogle Scholar
  61. 61.
    Schwartz Z, Soskolne W, Neubauer T, et al. Direct and sex-specific enhancement of bone formation and calcification by sex steroids in fetal mice long bone in vitro (biochemical and morphometric study). Endocrinology 1991; 129: 1167–74PubMedCrossRefGoogle Scholar
  62. 62.
    Migliaccio S, Newbold RR, Bullock BC, et al. Alterations of maternal estrogen levels during gestation affect the skeleton of female offspring. Endocrinology 1996; 137: 2118–5PubMedCrossRefGoogle Scholar
  63. 63.
    Trotter A, Maier L, Grill HJ, et al. Effects of postnatal estradiol and progesterone replacement in extremely preterm infants. J Clin Endocrinol Metab 1999; 84: 4531–5PubMedCrossRefGoogle Scholar
  64. 64.
    Trotter A, Bokelmann B, Sorgo W, et al. Follow-up examination at the age of 15 months of extremely preterm infants after postnatal estradiol and progesterone replacement. J Clin Endocrinol Metab 2001; 86: 601–3PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Section of Neonatology and Paediatric Critical Care Medicine, Children’s HospitalUniversity of UlmUlmGermany
  2. 2.Clinical PharmacyUniversity of UlmUlmGermany

Personalised recommendations